undamentalytics Newsletter
Sign in

Nexgel, Inc. income statement

In fiscal 2025, Nexgel, Inc. reported revenue of $11.4m, up 31.5% on the year before, operating income of −$3.4m (a -29.3% margin) and net income of −$3.0m, or −$0.38 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue21122491112
Cost of revenue211224678
Gross profit1−0−0000354
Research and development———00000—
Selling, general and administrative2223346810
Operating income−2−2−2−3−3−3−4−3−5
Interest expense————1000—
Income before tax————−5−3−3−3−6
Income tax—0000————
Net income−2−2−2−4−5−3−3−3−6
Diluted EPS−$0.01−$0.00−$0.04−$0.05−$0.85−$0.56−$0.50−$0.38−$0.74
Diluted shares (average)143m388m64m85m6m6m7m8m8m
EBITDA−2−2−2−2−3−3−3−3−4

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: NXGL vs SINTNXGL vs OSURMDXG vs NXGL

More: Health Care Supplies stocks compared, Health Care sector, rankings of US companies

Figures from Nexgel, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Nexgel, Inc.